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Abstract
Two commercial multivalent vaccines against vibriosis, caused by Vibrio anguillarum serotype(s) and photobacteriosis, 
caused by Photobacterium damsela subsp. piscicida, one with oil adjuvant (AJ) and the other, being an aqueous solution (AV), and 
an experimental monovalent (Ph. damselae subsp. piscicida) vaccine inactivated with formalin or heat, namely EVF and EVH, 
were tested in laboratory trials on sea bass (Dicentrarchus labrax) with respect to their efficacy against experimentally induced 
photobacteriosis.
The first trial aiming at high bacterial pressure was carried out 34 days post-vaccination and resulted in 90% mortalities in the 
control. The relative per cent survival (RPS) of vaccinated fish was calculated at 24, 3.7, 0 and 0 for the AJ, AV, EVF and EVH 
formulations, respectively. The second trial aiming at medium bacterial pressure was carried out 49 days post-vaccination and resulted 
in 45% mortalities in the control. The relative per cent survival (RPS) of vaccinated fish was calculated at 100, 92.7, 77.8 and 66.7 for 
the AJ, EVF, EVH and AV formulations, respectively. Apparently, under both these high and medium bacterial pressure conditions, 
the commercial vaccine AJ performed better than the commercial vaccine AV, while under medium pressure there was no statistical 
difference between the performance of EVF and AJ. The measurement of specific antibody titers in sera collected from all fish groups 
49 days post-vaccination, showed high levels in the fish vaccinated with the AJ vaccine, almost three times lower levels for the AV and 
EVF vaccines and even lower levels for the EVH vaccine. Results are discussed with respect to the choices available to mariculture 
companies in selecting a commercial vaccine against photobacteriosis and possible alternatives, which, if commercially developed, 
may reduce the cost of vaccination.     
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Introduction
Mariculture of sea bass (Dicentrarchus labrax, L.) 
and sea bream (Sparus aurata, L.) faces disease problems 
of viral, bacterial and parasitic etiology (Athanassopoulou 
& Bitchava, 2010). The most important bacterial 
diseases, vibriosis and photobacteriosis, are caused by 
different serotypes of the Gram negative bacteria Vibrio 
anguillarum (Sorensen & Larsen, 1986; Toranzo & Barja, 
1990) and Photobacterium damselae subsp. piscicida 
(Bakopoulos et al., 1995), respectively. Cultivated fish, 
and especially sea bass that reportedly appear to be 
much more sensitive than sea bream (Athanassopoulou 
& Bitchava, 2010) to both pathogens, are protected to 
a certain extend by vaccination and general hygiene 
measures. Vaccinating millions of individuals per 
mariculture venture is a copious activity that disrupts the 
routine on-growing procedure and entails high labour 
costs, long periods of administration and fish stock losses 
due to the development of stress and injuries, especially 
with individually administered vaccines. Due to the latter 
reasons, there is a tendency to minimize vaccination 
applications during the life span of cultivated sea bass, 
which can be from 15 to 18 months, to the expense of 
better protection through anamnestic administrations. 
Commercially available vaccines against either vibriosis 
or photobacteriosis (consisting of inactivated whole 
bacterial cells) have been available for quite some time 
with good protection against vibriosis (Woo & Bruno, 
1999) and variable results regarding photobacteriosis, 
especially in the field (Nakai et al., 1992; Le Breton, 1999, 
2009; Romalde, 2014). Another issue that stems from the 
problems associated with intraperitoneal (i.p.) vaccination, 
in particular, is that although at the beginning companies 
were vaccinating fish with monovalent or bivalent (two 
serotypes of V. anguillarum) vaccines against vibriosis 
or photobacteriosis, more recently, multivalent vaccines 
have been manufactured containing serotypes I & II of V. 
anguillarum and Ph. damselae subsp. piscicida inactivated 
bacterial cells. The production of such products was also 
dictated by the need for a single vaccine application. 
However, there are no published scientific data on the 
protection efficacy of these multivalent products. This, 
and especially the case for protection efficacy against 
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photobacteriosis, prompted our group to investigate the 
efficacy of these vaccines.
Thus, the objective of this study was to compare the 
two commercial and an experimental vaccine (inactivated 
with formalin or heat) in terms of protection of i.p. 
vaccinated sea bass against experimental infection with 
Ph. damselae subsp. piscicida (hereafter, Phdp).
Materials and Methods
Bacteria  
A Phdp strain isolated in Greece in North Evoia 
during a natural photobacteriosis outbreak affecting sea 
bass in the summer of 2012 was used throughout this 
study. The isolate was a kind donation of Dr L. Papanna, 
Nireus S.A. The isolate was kept at -85oC on cryobeads 
(Protect, Heywood, Lancs., UK). For the initiation 
of culture, a microbead was added directly to a small 
volume of growth medium.
Both on arrival and every time we were initiating a 
culture from the freezer, bacterial colonies were tested 
with the API 20E system of Biomérieux, following the 
instructions of the manufacturer but using 2% NaCl as 
diluent for the bacterial colonies.
Concentrations of bacteria in solution were 
determined by measuring the OD605. The optical reading 
was compared against a standard curve that we had 
previously constructed (OD605 versus bacterial cells/
ml) using plate counts of bacterial colonies of various 
dilutions of bacterial suspensions with known OD605.
Media and culture conditions
For maintenance purposes or the initiation of culture, 
the isolate was cultured in brain heart infusion broth 
(BHIB) (Oxoid, Hampshire, UK) supplemented with 
NaCl at a final concentration of 2%.
For the preparation of the experimental vaccine, the 
Phdp isolate was grown in the liquid media described 
by Bakopoulos et al. (2003) for 48h at 21 ± 0.5oC. All 
chemicals were supplied by Sigma Chemical Company, 
St Louis, MD, USA, unless otherwise stated.
 Commercial and experimental vaccine
Two commercially available vaccines against 
photobacteriosis were utilized in this study. According to 
the label attached to each of the commercial vaccines, 
they had the following characteristics: 
AJ, is a vaccine formulation for i.p. injection; it 
contains inactivated cultures of the bacteria V. anguillarum 
(serotype I), Phdp and a non-mineral oil adjuvant. This 
vaccine is in the form of water-in-oil emulsion.
AV, is a vaccine formulation that can be used in 
both immersion and i.p. injection; it contains formalin-
inactivated cultures of the bacteria V. anguillarum 
785KID and MSC275 (serotype I & II) and Phdp, and is 
an aqueous solution without adjuvant. 
The experimental vaccine was prepared as described 
by Bakopoulos et al. (2003) but modified so that the 
culture liquid was not separated from bacterial cells. 
The bacterial cells concentration in the vaccine mixture 
was 109 bacterial cells/ mL. A sample was then taken for 
the measurement of protein and carbohydrate content in 
the supernatants. Part of the bacterial mixture was then 
formalin-inactivated as described by Bakopoulos et al. 
(2003) and this experimental vaccine mixture is referred 
to as EVF, hereafter. The other part of the bacterial mixture 
was heat inactivated at 57oC for 30min. This experimental 
vaccine mixture is referred to as EVH, hereafter. 
Measurement of protein and carbohydrate concentration
Samples collected from the mixture of the 
experimental vaccine were analyzed for protein 
and carbohydrate content as described previously 
(Bakopoulos et al., 2003). 
Fish, tank and aquarium system
Seven hundred and fifty (750) non-vaccinated, healthy 
sea bass juveniles weighing approximately 1g, were kindly 
donated by Selonda S.A., Loutra facility, Lesvos. Fish 
were transferred under sedation (0.01% phenoxyethanol) 
to the wet laboratory facilities of the Department of Marine 
Sciences, University of The Aegean, Lesvos, Greece and 
were placed in five separate tanks. Fish were fed twice 
daily at 4% /kg body weight/day , with commercial feed 
of the appropriate size until reaching an average weight of 
10g (at about 8 weeks), in order to be vaccinated. One day 
before and one day after any handling, the fish were fasted, 
while handling was always performed after anaesthesia 
(0.1% phenoxyethanol).
The health status of fish during this period was 
assessed daily by observation (normal activity, feeding 
activity, reaction to stimuli, recording of any external 
disease signs or mortality) and found to be normal. 
A microbiological sampling was performed prior to 
the initiation of vaccination and prior to experimental 
infection to confirm that the fish were indeed not infected 
by an infectious agent. These tests were all negative for 
the presence of bacteria.
Growing and vaccinated fish were kept in a closed 
marine water recirculating system comprising 8 circular 
tanks with a conical bottom and a holding capacity of 2m3 
each, i.e. a total of 16m3, a sand filter, a 110W UV water 
sterilization unit, a biological filter, a marine water pump 
with 9m3/h water flow capacity and air pumps distributing 
air to all the tanks through air stones. The tank system 
water was partially (1/3) renewed every 4 months.
Infected fish were kept in a static plastic aquaria system, 
comprising 15 aquaria of 50L capacity and air pumps 
distributing air to all the aquaria through air stones. Water in 
the aquaria system was partially (1/2) renewed daily. 
Both systems were cleaned by fish excrements and 
uneaten food, and water parameters were monitored, 
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daily. Temperature ranged between 15.2oC in early spring 
and 24.05oC in mid-summer. Oxygen concentration 
ranged between 8.5mg/L in early spring and 5.7mg/L 
in mid-summer. Total ammonia concentration never 
exceeded 0.025mg/L throughout the experimental period. 
Vaccination
Five groups of 10g sea bass comprising 150 fish/
group were vaccinated i.p. with 50μL of each vaccine, 
with one group serving as control receiving the same 
volume of sterile 2% NaCl. The concentration of antigens 
in both the experimental vaccines per volume injected 
was 0.5x108 bacterial cells of Phdp, 1.9μg supernatants 
protein, 11.2μg supernatants carbohydrate without 
adjuvant, while both commercial vaccines contained 
the same number of bacterial cells. Further information 
cannot be provided because it is of proprietary nature.  
After vaccination, the fish were placed in their 
respective tanks. Toxicity of the various vaccines was 
monitored throughout the experimental period and 
recorded. Randomly sampled, moribund and recently 
dead fish resulting from the efficacy studies were 
dissected and macroscopically observed for the presence 
of pathological signs caused by vaccination in the 
abdominal cavity. Tissue samples were also processed 
for microscopic observation using routine procedures 
and stained with hematoxylin-eosin.  
Assessment of efficacy
The efficacy of the four vaccine formulations was 
assessed with two separate experimental infection trials, one 
resulting in heavy bacterial pressure and the other in milder 
bacterial pressure. Assessment of efficacy was initiated after 
28 days post-vaccination to allow for full development of 
immune response, according to the suggestion of one of the 
manufacturers of the commercial vaccines (AV).
The bacterial doses required to achieve high and 
mild bacterial pressure were determined prior to the 
initiation of the efficacy assessment by performing 
i.p. experimental infections of controls using various 
concentrations of bacterial cells. 
Thirty four days post-vaccination, 60 fish from each 
group were infected with an i.p. injection of 50μL of the 
Phdp isolate used in this study, grown in BHIB 2% NaCl 
for 48h at 21 ± 0.5oC. The dose of bacteria received by 
each individual fish was 1.75x105 cells. After infection, 
the 60 fish of each group were randomly divided into 
three groups of 20 fish and placed in separate aquaria. 
Mortalities were monitored and recorded daily and 
the experiment was stopped when no mortalities were 
recorded for two consecutive days.
The 2nd infection trial was performed 49 days post-
vaccination but in this case individual fish received 
3.25x104 bacterial cells. The rest of the experiment was 
performed as described above.
Protection conferred by the different commercial 
and experimental vaccine formulations was assessed as 
described by Amend (1981) by calculation of the relative 
per cent survival (RPS) using the following formula:
RPS = [1 –                                                               ]* 100
% mortality of immunized fish
% mortality of non immunized fish
Moribund and recently deceased fish were sampled 
with routine procedures for microbiological investigation 
in order to determine the cause of disease/death. 
Microbiological samples taken from the spleen and 
kidney were used to inoculate the surface of tryptone soy 
agar supplied with 2% NaCl, in petri dishes. Developed 
bacterial colonies were identified using the API 20E 
system (Biomérieux) using 2% NaCl as diluent.  
Measurement of specific immunoglobulins (IgMs) in 
sea bass serum samples 
Blood samples collected on day 49 (2nd trial) from 
all experimental groups were processed for the isolation 
of serum. Sera from each group were pooled and these 
samples were utilized in ELISA analysis (Bakopoulos 
et al., 1997) for the determination of specific IgM levels 
against Phdp. Results were read on a MR-96A microplate 
reader (MINDRAY).
Statistical analysis
Results were processed using the Kaplan-Meier 
survival curves (Kaplan & Meier, 1958).
In order to compare the survival distribution for all 
the different vaccine treatments and the two experiments 
as well as pairwise, the Log-rank test (Mantel, 1966) was 
employed, setting statistically different results at p<0.05. 
All statistical analyses were conducted with the use of 
the R software for Statistical Computing (R Core Team, 
2013) and the Survival Package (Therneau, 2013). 
Results
Toxicity-pathology evaluation
No mortalities in any group or vaccine formulation 
were recorded post-vaccination throughout the 
experimental period.
The macroscopic observation of internal organs in 
the abdominal cavity of vaccinated fish revealed none or 
mild reactions (localized erythema, mild inflammation at 
the point of injection) of fish vaccinated with the aqueous 
vaccine solutions (AV, EVF, EVH and 2% NaCl) and 
more severe reactions in fish vaccinated with the AJ 
vaccine (macroscopic data not shown). 
Localized aseptic lesions caused by an inflammatory 
response (concluded after microbiological examination) 
to the latter vaccine were observed in all the specimens 
examined. These lesions were round, raised, off-white to 
brownish in colour, their diameter ranged between 0.3 and 
1.2cm, they were located on the surface of the fatty tissue 
surrounding the gut and a vessel reticulum was clearly 
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evident around them. Microscopically, these lesions were 
characterized as aseptic granulomatous lesions (Fig. 1).
As evidenced in Figure 1A, consisting of 
granulomatous tissue at various developmental stages, the 
lesions have a core area of caseous necrosis tissue, mainly 
composed by oil (vacuoles), necrotic cells and debris 
(areas with dark colour). Externally, a layer of fibroblast-
like cells was present (arrowhead in Fig. 1A and letter F in 
insert B), with large amounts of associated collagen fibres 
(arrow in Fig. 1A and letter C in insert B). These findings 
are consistent with granulomatous peritonitis.
Efficacy of vaccines
Moribund and recently dead fish, due to the 
experimental infections that were microbiologically 
sampled, were all found positive for Phdp.
High Infection Pressure Experiment
The high infection pressure experiment resulted in 
90% cumulative mortality in the controls The experiment 
lasted nine days and the final cumulative mortalities and 
RPS achieved for all the groups of fish is shown in Table 1.
The experimental EVH and EVF vaccines conferred 
no protection to the respective vaccinated fish groups. In 
contrast, an RPS value of 24% and 3.7% was calculated 
for the AJ and the AV commercial vaccines, respectively. 
Apparently, the protection efficacy of the AJ vaccine was 
superior by far compared to the AV commercial vaccine, 
under these experimental conditions. 
The Kaplan-Meier survival curves for the LD90 
experiment are presented in Figure 2.
Evidently, survival rates dropped steeply for all 
vaccine groups except the AJ group.
Table 1. Cumulative mortalities and RPS values for all groups in both trials. LD90 bacterial dose, 9 days post-challenge, 34 days 
post-vaccination & LD45 bacterial dose, 15 days post-challenge, 49 days post-vaccination.
Fish Groups No of fish Specific loss % fish mortality RPS value
*LD90 Exp.
**LD45 Exp. LD90 Exp. LD45 Exp. LD90 Exp. LD45 Exp.
LD90 
Exp.
LD45 
Exp.
Control 3x20 3x20 54 27 90 45 - -
AJ 3x20 3x20 41 0 68.4 0 24 100
AV 3x20 3x20 52 9 86.7 15 3.7 66.7
EVF 3x20 3x20 58 2 96.7 3.3 0 92.7
EVH 3x20 3x20 60 6 100 10 0 77.8
Fig. 1: A: Granulomatous tissue at various stages of development (10x magnification). Insert B: Detail of a formed granuloma 
(40x magnification). Haematoxylin-eosin.
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In order to compare the survival distribution for the all 
different vaccine treatments as well as pairwise, the Log-
rank test (Mantel, 1966) was employed. Comparisons 
of the differences between the five different treatments 
(controls and vaccines) in the experiments were found 
statistically significant (p < 0.05). Most pairwise 
comparisons of differences were statistically significant 
(p < 0.05). The non-significant differences observed in 
the LD90 experiment were between the EVF vaccine and 
the control (p = 0.756).
Medium Infection Pressure Experiment
The medium infection pressure experiment resulted 
in 45% cumulative mortality in the controls. The 
experiment lasted fifteen days and the final cumulative 
mortalities and RPS achieved for all the groups of fish is 
shown in Table 1.
Fish vaccinated with the commercial AJ vaccine 
were 100% protected, as evidenced by the respective 
RPS value that was calculated. The performance of 
the experimental EVF vaccine conferring 92.7% RPS, 
followed by the EVH vaccine with 77.8% RPS, was also 
notable, while lower performance was observed by the 
AV commercial vaccine achieving a 66.7% RPS value. 
The Kaplan-Meier survival curves for the LD45 
experiment are presented in Figure 3.
Evidently, survival rates dropped comparatively 
steeply for the control fish groups over a long period, 
which was longer for the AV groups but with a milder 
drop in survival rates, while, these rates for the EVH and 
EVF groups, after a steep and short drop, were stabilized. 
The application of the Log-rank test for these results 
showed that the comparison of the differences between 
the five different treatments (controls and vaccines) in the 
experiments were found statistically significant (p < 0.05). 
Most pairwise comparisons of differences were statistically 
significant (p < 0.05). The non-significant differences 
observed for the LD45 experiment were between the AV 
and EVH vaccine (p = 0.48), AJ and EVF vaccine (p = 
0.156) and EVH and EVF vaccines (p = 0.138). 
The RPS results obtained from both high and medium 
bacterial pressure experimental infection trials for the 
vaccines used are visualized in Figure 4 along with fitted 
linear regression lines. RPSs were related to the different 
bacterial doses achieving the LD45 and LD90 effect. These 
values were log10 transformed.
Comparing these data it is expected that both the AJ 
and the EVF vaccines would perform better with respect 
to the RPS achieved up to a certain bacterial pressure and 
as this pressure is closer to causing 90% mortality in the 
controls, EVF is replaced by the AV vaccine in terms of 
the RPS achieved.  
Levels of specific anti-Phdp IgM in sea bass sera
The levels of specific antibody titers against Phdp from 
all the vaccinated groups and controls on the start day of the 
2nd trial (day 49 post-vaccination) measured as absorbance 
at 450nm with ELISA analysis, are presented in Figure 5. 
Obviously, specific antibody levels against Phdp for the fish 
vaccinated with the AJ vaccine were very high, followed 
by the commercial AV vaccine and the experimental EVF 
vaccine that showed similar levels. The lowest antibody 
levels were measured for the EVH formulation. 
Discussion
Although there are previous studies on the protection 
efficacy achieved post-vaccination with monovalent (and 
bivalent with serotypes I and II) vaccines either against 
V. anguillarum (Viale et al., 2006; Galeotti et al., 2013) 
or against Phdp (Magarinos et al., 1994; Magarinos et al., 
1994a), information on the protection efficacy when fish are 
vaccinated with bivalent vaccines against both pathogens 
Fig. 2: Kaplan-Meier survival curves for the LD90 experiment. 
Plus signs indicate right censored data.
Fig. 3: Kaplan-Meier survival curves for the LD45 experiment. 
Plus signs indicate right censored data.
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is scarce [only the inconclusive article of Gravningen et al. 
(1998), regarding photobacteriosis]. Protection conferred 
post-vaccination against V. anguillarum is reportedly 
effective (Athanassopoulou & Bitchava, 2010; Galeotti 
et al., 2013). In contrast, protection conferred post-
vaccination against Phdp is variable (Nakai et al., 1992; 
Le Breton, 1999, 2009; Romalde, 2014). For the former 
and latter reasons, in this study it was decided to compare 
two commercially available vaccines and an experimental 
vaccine against fish photobacteriosis in terms of protection 
of intraperitoneally (i.p.) vaccinated sea bass against 
experimental infections with Phdp, designed to exert 
extreme and average bacterial pressures.
Neither the commercial or the experimental vaccines 
caused mortality or other noticeable effects on the 
wellbeing of vaccinated fish. Internally, however, the fish 
groups that were vaccinated with the AJ vaccine (water-in-
oil emulsion) showed abdominal adhesions and developed 
granulomatous peritonitis. These findings are consistent 
with the findings of Afonso et al. (2005) and Poppe 
& Koppang (2014). The extent to which these aseptic 
inflammatory responses can influence the functioning of 
the digestive system remains to be investigated. The other 
groups showed none to very mild adhesions. 
In order to evaluate how the various groups of 
vaccinated fish respond to high and medium bacterial 
pressure, two separate challenges were performed. To 
our knowledge this is the first time that performance of 
the same vaccinated groups is evaluated under different 
challenge pressures, performed a short period apart.
Results showed that, in both challenges, the groups that 
were vaccinated with the adjuvanted commercial AJ vaccine 
responded better compared to all the other commercial or 
experimental vaccines, achieving RPS values of 24% and 
100%, for the LD90 and LD45 challenges, respectively. In 
contrast, fish groups vaccinated with the aqueous commercial 
vaccine AV, achieved an RPS value of only 3.7% in the 
Fig. 5: Specific sea bass serum antibody titers against Phdp 49 
days post-vaccination with the various vaccines.
Fig. 4: Relative percentage of survival (RPS) for different lethal doses (values transformed Log10) and different vaccines. Linear 
regression equations as follows: AJ: y = -103.7x + 567.6, R2 = 0.98, p < 0.0001,  AV: y = -83.2x + 442, R2 = 0.71, p = 0.0358, EVF: 
y = -126.4x + 662.8, R2 = 0.98, p = 0.0002, EVH: y = -106.4x + 557.9, R2 = 0.9, p = 0.0035.
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LD90 challenge, and both the experimental vaccines failed 
to confer any protection at all. The latter result was very 
interesting because it contradicts the very good protection 
that was described in the Bakopoulos et al. (2003) study 
for the experimental vaccines that were assessed here. The 
differences between the two experiments were that in this 
study a higher cumulative mortality was achieved, the entire 
bacterial culture was used as the vaccine without prior 
isolation of bacterial cells and ECPs, and the challenge was 
performed with Phdp grown in BHIB 2% NaCl. Despite 
the fact that the culture medium plays a very important role 
in the antigens that a pathogen synthesizes and virulence 
(Bakopoulos et al., 2003a; Bakopoulos et al., 2004), the 
differences in challenge severity and the modification of the 
preparation method applied for the experimental vaccine, 
may account for the contradictory results obtained in this 
study. Unfortunately, protection of vaccinated sea bass 
against photobacteriosis under such extreme conditions 
cannot be compared with previous studies.     
Very different results were obtained when the 
milder LD45 challenge was performed. In this case, the 
RPS values obtained were in descending order, 92.7%, 
77.8% and 66.7% for the fish groups vaccinated with the 
EVF, EVH and commercial AV vaccine, respectively, 
while the RPS value achieved by the AJ reached 100%. 
In this case, there was no statistical difference between 
the commercial AJ and the experimental EVF vaccines 
and between the experimental EVH and the commercial 
Aqua Vac vaccines. Furthermore, as it is evident from 
this challenge, heat inactivation of the experimental 
vaccine (EVH) had a deleterious effect on the protection 
conferred against photobacteriosis compared to formalin 
inactivation (EVF), despite the fact that no statistical 
difference was calculated.  This is probably due to higher 
antigen destruction by heating as demonstrated in earlier 
studies (Levings, 1984; Samoylova et al., 2012). The 
results obtained in this study cannot be directly compared 
to the previous study of Bakopoulos et al. (2003) because 
of the different conditions between the two experiments; 
however, results for the experimental EVF vaccine are 
comparable. Vaccines containing ECPs seem to perform 
better compared to vaccines composed of bacterial cells 
only (Magarinos et al., 1994), as is the case for the 
commercial vaccines tested here.
The analysis of sea bass sera collected on the start day 
of the 2nd efficacy assessment trial, as regards the levels of 
specific anti-Phdp antibodies, correspond very well with 
the performance of the commercial AJ vaccine only, for 
which high antibody levels were measured. Interestingly, 
there was no correlation between the levels of specific 
anti-Phdp antibodies in the sea bass sera collected from 
the other experimental groups and the performance of 
the respective vaccines. The adjuvant included in the AJ 
vaccine acts in a beneficial way, increasing the levels of 
antibodies even at 49 days post-vaccination in contrast 
to the other formulations that did not contain an adjuvant 
where antibody levels were indisputably much lower. 
Protection against the infection, however, is not a matter 
of quantity but rather of quality as discussed below. 
Apparently, the results obtained from this study suggest 
that the commercial AJ vaccine acts better in comparison 
to the commercial AV vaccine as regards protection against 
the experimental challenge with Phdp, under the described 
conditions. This better performance was demonstrated 
under both extreme and medium bacterial pressure. The 
differences between the two product formulations, based 
on the information provided by the producers, consist 
mainly in the inclusion of a non-mineral adjuvant in the 
AJ vaccine and the fact that the bacterial cells included 
in the AV vaccine were grown in both normal and iron-
limited media. Each of these differences is beneficial for 
different reasons. Adjuvants cause intense attraction of 
various types of leukocytes at the location of the vaccine 
and may have a prolonged effect because of slower antigen 
release (Afonso et al., 2005). These may have a positive 
quantitative stimulation effect on the immune response. 
Bacterial growth under iron limitation conditions leads 
to the expression of antigens that may be involved in 
virulence (Magarinos et al., 1994b; Bakopoulos et al., 
1997a) and, thus, may exert a positive qualitative effect on 
immune response and protection.
Regarding the experimental vaccine formulations, 
no protection was conferred under extreme conditions of 
infection, but a completely different case was revealed 
under medium infection pressure. In these conditions, the 
EVF vaccine conferred protection against Phdp infection 
in a similar manner to the commercial AJ vaccine, despite 
the fact that it does not contain adjuvants. It seems that 
the qualitative characteristics of the antigens included 
(Bakopoulos et al., 2003a) have an “added-value” 
in terms of protection, comparable to an adjuvanted 
formulation. The EVH formulation was inferior to the 
EVF but apparently performed somewhat better than the 
AV vaccine. At practical level, this study suggests that the 
adjuvanted AJ vaccine needs to be used in areas where 
a high Phdp stress is foreseen, whereas under milder 
pressure the aqueous AV or an improved formulation, 
such as the EVF formulation without any adjuvant could 
be the alternative if commercially developed. This could 
reduce both the cost of the vaccine formulation and the 
effects of the adjuvant on the abdominal cavity.   
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